Listen & Watch

1. Can We Do Better? Current & Future Realities of mRNA Process Development 8/7/2024

   There’s been great progress in establishing processes and platforms for linear mRNA vaccines — but where does this current know-how fall short for those exploring linear and next-gen RNA constructs for therapeutic (non-vaccine) products?

2. Opening The “Black Box” Of The mRNA Regulatory Paradigm 5/2/2024

   This Advancing RNA panel discussion covers the broad learnings therapeutics developers can (or can’t) adapt from the previously approved mRNA vaccine products, and what an “ideal” RNA therapeutics regulatory paradigm could look like

3. Got Raw Materials? The State Of The mRNA Supply Chain 2/21/2024

   This discussion delves into how Advancing RNA can address concerns over the current “health” and availability of both small- and large-scale RNA therapeutics.

4. mRNA For Cancer Immunotherapy: 2024 Outlook 12/5/2023

   As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.

5. mRNA Update: Beyond Prophylactic Vaccines 10/10/2023

   mRNA-based therapeutics are widely regarded as a “next big thing” in biopharma, but manufacturing them is fraught with complex challenges. Check out this digital event from Bioprocess Online Live featuring a discussion with mRNA process development experts on the front lines of the mRNA therapeutics revolution.

6. Risk Reduction In mRNA Therapeutic Development 9/13/2023

   mRNA is at an inflection point. To reach its therapeutic potential in chronic, and even rare, disease applications, some biopharmaceutical manufacturing fundamentals must be addressed.

7. Major Trends In Next-Gen RNA Engineering 6/13/2023

   From tissue specificity to potency and durability, major trends in RNA are developing as the space continues to evolve at record-breaking speed. In June 2023, Cell & Gene Live welcomed Nathaniel Wang, CEO and Co-Founder, Replicate Bioscience and Sam Deutch, EVP of Research and Early Development at Nutcracker Therapeutics for a deep dive into how RNA can accelerate drug development and how the evolution in the scale-up production of novel engineering technologies impacts near- and long-term deployment of new therapies.

8. Revolutionary Incrementalism: Future-Proofing mRNA Drug Manufacturing 3/28/2023

   Industry experts share go-to best practices, suggestions, and experiences for prioritizing and streamlining technical operations endeavors to prepare mRNA therapeutics companies for the clinic and, eventually, the commercial market.

9. LNPs & Beyond: Opportunities In RNA Delivery 10/6/2022

   The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the importance of mRNA/RNA therapeutics. For those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening their applicability, durability, and effectiveness.

10. Cell & Gene Live Audience Q&A 9/16/2022

    During the hour, audience members submitted their questions for our panelists. To no surprise, they asked thoughtful, solid questions on everything from transecting cells with multiple RNA and the challenges associated with chronic dosing of mRNA therapeutics to the regulatory challenges around mRNA cell therapies.